View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 3, 2018

Oncimmune to offer cancer detection platform in Chinese market

UK-based Oncimmune has signed a framework agreement with Genostics, a Chinese molecular diagnostics marketing and distribution firm, for an exclusive licence of its EarlyCDT platform designed for the early detection of cancer.

UK-based Oncimmune has signed a framework agreement with Genostics, a Chinese molecular diagnostics marketing and distribution firm, for an exclusive licence of its EarlyCDT platform designed for the early detection of cancer.

The agreement covers distribution, manufacturing and future development of products associated with the EarlyCDT platform in the People’s Republic of China.

The firms will initially focus on the EarlyCDT-Lung product, with plans to begin sale within 36 months of the date of the agreement, subject to approval from the China Food and Drug Administration (CFDA).

Genostics’ sister company GeneTech will carry out the manufacturing, marketing and distribution of EarlyCDT-Lung.

Under the terms of the agreement, Oncimmune is set to obtain minimum royalty payments of £15.7m on aggregate during the first six years after market entry.

“This deal means we can now offer early detection of cancer, which augments our product portfolio in our specialised area of pathology and oncology.”

The company will receive £10m investment from Genostics at a 49% premium, which is subject to the approval of shareholders.

Genostics chairman Dr Cheung To said: “This deal means we can now offer early detection of cancer, which augments our product portfolio in our specialised area of pathology and oncology.

“The EarlyCDT platform is complementary to our current molecular diagnostic product line, which uses the latest PCR, sequencing and microarray technologies and, by combining forces with Oncimmune, we will accelerate the technological and commercial development of the EarlyCDT platform, which will ultimately benefit more Chinese patients.”

Oncimmune and Genostics also intend to consider the transfer of manufacturing to China, along with further research and development to advance the EarlyCDT platform technology for new prevalent cancers.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network